News & Publications

Foresight Diagnostics and partners present twelve studies demonstrating accuracy and utility of PhasED-Seq ctDNA platform for early response assessment at the 65th American Society of Hematology (ASH) Annual Meeting

AURORA, Colo., December 12, 2023 – Foresight Diagnostics, the leader in ultra-sensitive liquid biopsy MRD detection, announced multiple studies that consistently demonstrated higher clinical sensitivity and prognostic accuracy of Foresight Diagnostic’s PhasED-Seq circulating tumor DNA (ctDNA) technology compared to that of standard-of-care imaging in patients with lymphoma. These findings mark a significant milestone for accelerating clinical development, giving the scientific community the data needed to confidently shift clinical response assessment away from solely relying on radiographic imaging to now incorporating ultra-sensitive ctDNA measurement as an earlier and more accurate indicator of response or relapse. The new data have been presented across four podium presentations and two posters during this year’s American Society of Hematology (ASH) annual meeting. 

“These studies finally give us, as researchers and drug developers, the momentum we need to challenge the paradigm of how patients are tracked and treated in clinical trials and, ultimately, in clinical settings,” said Ash Alizadeh, MD, PhD, and co-founder of Foresight Diagnostics. “We are getting to a point where there are few use cases in lymphoma where PET/CT is better than ctDNA/MRD. As a community, it is time for us to evolve to methods that will allow us to innovate and provide solutions faster for patients.”

Research partners across these studies included Bristol Myers Squibb, ADC Therapeutics, National Center for Cancer Research, and several academic medical centers and universities across the US, Europe, and Asia. In addition to the six abstracts co-authored with Foresight Diagnostics, an additional six studies reported on ctDNA-MRD detection using Foresight’s PhasED-Seq platform. 

Studies co-authored by Foresight Diagnostics:

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study – in collaboration with Bristol Myers Squibb

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA – in collaboration with The National Center for Cancer Research

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World CtDNA Study

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma – in collaboration with ADC Therapeutics

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Additional studies utilizing PhasED-Seq ctDNA-MRD platform:

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma – authored by Bristol Myers Squibb and multiple research institutions

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion - authored by Bristol Myers Squibb and multiple research institutions

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma – authored by Seagen and other research institutions

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma – authored by MD Anderson Cancer Center

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma – authored by Stanford University and other research institutions

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD – authored by Fred Hutchinson Cancer Center and other research institutions

“Earlier indicators of treatment response with ultrasensitive ctDNA-MRD detection will allow us to improve treatment strategies and modify interventions when it is most critical for patients,” said Patrick van Berkel, Chief Scientific Officer at ADC Therapeutics. “We are pleased to share our findings at ASH specific to the molecular response and mutational genotypes seen in DLBCL patients undergoing treatment with Zynlonta (loncastuximab tesirine-lpyl [Lonca]) to collectively improve our approaches to using ctDNA for drug development and clinical decision making.”

A summary of each poster and presentation can be found here. Foresight Diagnostics and its fellow co-authors and partners thank the patients, caregivers, investigators, and study personnel involved in the trials that provided the data for this research. 

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests (with a detection limit below 0.0001%, or one part-per-million). The improved sensitivity of the Foresight’s MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and hematologic malignancies. For more information, please visit and follow us on Twitter and LinkedIn.  


About PhasED-Seq

The Foresight MRD platform is based on the Phased variant Enrichment and Detection by Sequencing (PhasED-SeqTM) technology. PhasED-Seq lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%). PhasED-Seq has been extensively tested in thousands of patient samples.


Contact Foresight

Phone: 720-443-3658 


Back to all